Publications by authors named "Markus Hinder"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

7,386

Total Likes

999

Extended Reach

154,063

Social Features

11
C
Changing R&D models in research-based pharmaceutical companies.
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder

J Transl Med· April 2016

Videos about Article: user user

2 9 4 26

View All Article and Social Media Activity
T
The R&D productivity challenge: transforming the pharmaceutical ecosystem.
Alexander Schuhmacher, Oliver Gassmann, Sebastian Kwisda, Malte Kremer, Markus Hinder

Drug Discov Today· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 (2a) Randomized Trial of Iscalimab in Adolescents and Young Adults with New-Onset Type 1 Diabetes.
Chantal Mathieu, Michelle Quinlan, Kristina Wagner, Jill Kompa, Nicole Hartmann, Markus Hinder

Diabetes Technol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Data Monitoring Committees in drug research.
Markus Hinder, Nandhini Madesh, Dominik Hartl, Alexander Schuhmacher

Drug Discov Today· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the editor of the Brit J Clin Pharmacol on Heuberger et al. 2025 https://doi.org/10.1002/bcp.70090.
Markus Hinder, Vikram P Sinha

Br J Clin Pharmacol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)" [Drug Discov. Today 30(2) (2025) 104291].
Alexander Schuhmacher, Markus Hinder, Elazar Brief, Oliver Gassmann, Dominik Hartl

Drug Discov Today· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.
Beryl B Cummings, Mark P Joing, Page R Bouchard, Mark N Milton, Peter F Moesta, Markus Hinder

Lancet· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood Pressure Lowering Effects of a Novel Long-Acting NPR1 Agonist, XXB750, in Healthy Participants: A Randomized, First-in-Human Clinical Study.
YanLing He, Xueping Wu, Andre Serra-Roma, Maggie Markiewicz, Emma Healy, Markus Hinder

Circulation· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies.
Alexander Schuhmacher, Kyrylo Grinchenko, Oliver Gassmann, Dominik Hartl, Markus Hinder

Drug Discov Today· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022).
Alexander Schuhmacher, Markus Hinder, Elazar Brief, Oliver Gassmann, Dominik Hartl

Drug Discov Today· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of FDA approvals by top 20 pharma companies (2014-2023).
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder, Dominik Hartl

Drug Discov Today· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is the blockbuster imperative broken?
Alexander Schuhmacher, Markus Hinder, Nikolaj Boger, Oliver Gassmann, Dominik Hartl

Drug Discov Today· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating the origins of recent pharmaceutical innovation.
Alexander Schuhmacher, Markus Hinder, Alexander Dodel, Oliver Gassmann, Dominik Hartl

Nat Rev Drug Discov· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of pharma R&D productivity - a new perspective needed.
Alexander Schuhmacher, Markus Hinder, Alexander von Stegmann Und Stein, Dominik Hartl, Oliver Gassmann

Drug Discov Today· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acceptability of multiple coated mini-tablets in comparison to syrup in infants and toddlers: a randomised controlled study.
Viviane Klingmann, Markus Hinder, Thomas H Langenickel, Fabian Chen, Yasser Khder

Arch Dis Child· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The significance of blockbusters in the pharmaceutical industry.
Alexander Schuhmacher, Markus Hinder, Nikolaj Boger, Dominik Hartl, Oliver Gassmann

Nat Rev Drug Discov· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open innovation: A paradigm shift in pharma R&D?
Alexander Schuhmacher, Oliver Gassmann, Doria Bieniok, Markus Hinder, Dominik Hartl

Drug Discov Today· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age-related macular degeneration.
Nadia Zakaria, Nicolas Guerard, Andres Emanuelli, Pravin Dugel, Jen Watts, Markus Hinder

Pharmacol Res Perspect· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia.
Daniel J Rader, Eleftheria Maratos-Flier, Amanda Nguyen, Doug Hom, Michael Ferriere, Markus Hinder

J Clin Endocrinol Metab· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic risk identification and assessment using a new risk map in pharmaceutical R&D.
Alexander Schuhmacher, Clara Brieke, Oliver Gassmann, Markus Hinder, Dominik Hartl

Drug Discov Today· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial.
Susanne Tan, Stanislav Ignatenko, Frank Wagner, Anuja Dokras, Jochen Seufert, Markus Hinder

Diabetes Obes Metab· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A framework to guide dose & regimen strategy for clinical drug development.
Oliver Sander, Baldur Magnusson, Inga Ludwig, Astrid Jullion, Christophe Meille, Markus Hinder

CPT Pharmacometrics Syst Pharmacol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence.
Alexander Schuhmacher, Alexander Gatto, Michael Kuss, Oliver Gassmann, Markus Hinder

Drug Discov Today· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
R&D efficiency of leading pharmaceutical companies - A 20-year analysis.
Alexander Schuhmacher, Lucas Wilisch, Michael Kuss, Andreas Kandelbauer, Markus Hinder

Drug Discov Today· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational precision medicine: an industry perspective.
Dominik Hartl, Valeria de Luca, Anna Kostikova, Jason Laramie, Scott Kennedy, Markus Hinder

J Transl Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2, in patients with chronic kidney disease: A randomized trial.
YanLing He, Alok Pachori, Ping Chen, Shenglin Ma, Anisha E Mendonza, Markus Hinder

Diabetes Obes Metab· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis